


BELGIUM WALLONIA

@HEALTH TECHNOLOGIES | MISSION TO MINNESOTA





Wallonia has an excellent logistics infrastructure and «multimodality» is the keyword. Liege Airport was awarded the title of best cargo airport in the world for the year 2020. You will also find yourself well supported: the actors of the sector are gathered in the «Logistics in Wallonia» cluster.



WALLONIA EXPORT & INVESTMENT AGENCY

The Wallonia Export & Investment Agency (AWEX) is the institution in charge of the development and management of Wallonia's domestic and international economic relations.

Through a personalized, innovative, and sustainable approach, AWEX supports Walloon companies - regardless of their size, sector, or target market - in every step of their international endeavors. This includes exports, technological partnerships, and development abroad.

The agency's vast network of connections ensures the best advisors are always by your side. Our local anchors and agents abroad are capable of providing unparalleled insight to take your company to the next level. In addition, our connections will help establish your business in the global marketplace and promote it throughout the world. Training, incentives, and international financing are also available.

AWEX is also committed to strengthening Wallonia's position as the premier gateway for international investors seeking success in the heart of Europe. We work closely with them to inform, convince, and advise in every stage of their development.

Feel free to get in touch with one of our local or international agents via our websites listed above.

In our network of more than 400 employees in nearly 100 countries around the world, there is always someone ready and willing to support you in your approach.

Place Sainctelette 2 B - 1080 Brussels Email: info@awex.be

Websites: www.awex-export.be http://www.investinwallonia.be/key-sectors/ life-sciences www.wallonia.be Facebook: Wallonia Export | Facebook

Facebook : Wallonia Export | Facebook LinkedIn: https://www.linkedin.com/company/wallonia-export-investment-agency/

Mrs Pascale DELCOMMINETTE, CEO



In attendance at HEALTH TECHNOLOGIES



Stephano SMARS, Trade Commissioner - AWEX Chicago

E-mail: chicago@awex-wallonia.com

Quentin DERZELLE, Trade Commissioner - AWEX New York

E-mail: newyork@awex-wallonia.com



BioWin - The Health Cluster of Wallonia

BioWin is the health cluster in Wallonia, Belgium, the regional reference for all stakeholders in biotech, e-health and medtech research and innovation projects. It includes 250 members from the private, public and academic sectors.

Its mission is to accelerate innovation to meet tomorrow's public health challenges and develop the knowledge, employment and competitiveness of the life sciences ecosystem in Wallonia.

Founded in 2006, BioWin brings together all the innovation players in Wallonia's health-tech field, with the goal of stimulating regional economic redeployment. The cluster is also involved in implementing the sector's industrial policy (industrial innovation and research, training, and support for business growth).

Business Village Ecolys Avenue d'Ecolys 2 B - 5020 NAMUR Email: contact@biowin.org

Website: www.biowin.org

LinkedIn:

https://www.linkedin.com/company/biowin/

Mrs Sylvie PONCHAUT, CEO

DELEGATE:
Damien DIOP, Head of Membership & International
Development

Mobile: +32 472 19 80 91 E-mail: Damien.Diop@biowin.org



PARTICIPANTS

- 08 CERHUM
- 09 CORQUEST
- 10 GABISMARTCARE
- 11 HEARTKINETICS
- 12 LYS MEDICAL
- 13 MECATECH CLUSTER
- 14 NEUROPATH
- 15 SYNERGIA MEDICAL

MEDICAL DEVICES

- CERHUM BONE GRAFTING
- CORQUEST MITRAL VALVE REPAIR *
- LYS MEDICAL ENDOSCOPIC DEVICE LUNG BIOPSIES **
- SYNERGIA MEDICAL NEUROLOGIC DISORDERS ***

DIGITAL HEALTH - IT FOR HEALTH

- GABI SMARTCARE PEDIATRIC HEALTHCARE
- HEARTKINETICS HEART FAILURE DETECTION * | DETECTION OF

 CARDIOTOXIC EFFECT OF CANCER TREATMENT **
- NEUROPATH NEURODEGENERATIVE DISEASES SUCH AS PARKINSON'S
 DISEASE ***
- * CARDIOLOGY ** ONCOLOGY *** NEUROLOGY

CLUSTERS

- BIOWIN THE HEALTH CLUSTER OF WALLONIA
- MECATECH WALLOON CLUSTER IN MECHANICAL ENGINEERING

CERHUM

CORQUEST





Avenue du Parc industriel 89 B - 4000 LIEGE

E-mail: info@cerhum.com Website: www.cerhum.com

DELEGATE:

Grégory NOLENS, CSO (PhD) Mobile: +32 477 44 34 81 E-mail: gregory.nolens@cerhum.com



Rue de l'étang 33 B - 1320 BEAUVECHAIN Website: www.corquest.tech

DELEGATE:

Olivier DECUYPERE, CEO Mobile: + 32 493 36 79 46 E-mail: olivier@corquest.tech

CERHUM is specialized in bone reconstruction. Our main solution is called MyBone: an advanced 3D bone graft which avoids autograft and owns superior bone reconstruction performances.

Our flagship product, MyBone Custom, is an innovative patient-specific bone graft for repairing people suffering from facial bone gaps and deformities. Our main users are Maxillofacial, Dental, ENT and Plastic surgeons for trauma, congenital, implantology and esthetic applications. MyBone solution mixes 3D printing of bioceramic with patented porosity and suitable mechnical properties.

In addition, Cerhum offers MyBone solution as CDMO to Medical manufacturers for bone graft using standard shapes (spine fusion, orthopedic, ...).

MyBone is sold in Europe. In the US, a first 510(k) is in progress, and Q-Sub has been submitted.

Cerhum is actively looking for partners:

- to clinically use our product - distribute our product - integrate our solution in their portfolio CERHUM manufactures MyBone: an advanced bone graft which avoids autograft and superior bone

KEY ACHIEVEMENTS

Development of MyBone: an advanced bone graft for bone reconstruction with two World Premieres

- MyBone Custom on European market: patient specific bone graft for custom bone reconstruction
- Collaboration with Distributors in Europe
- First collaboration in US for Contract Manufacturing in Spine
- First 510(k) and a second Q-Sub submitted at the FDA,
- Grants for different research projects for product development :
 - o Cranial and maxillofacial implants
 - o Dental bone graft
 - o Vascularization of MyBone for big defects
 - o Orthopedic bone graft with BMP2
 - o And other projects to improve MyBone et the process
- Scientific committee with Key Opinion Leaders
- Medical certification ISO 13485
- Patents on the products

An early stage start-up aiming at developing new technologies focused on heart and vascular diseases that increase efficacy while reducing invasiveness. CorQuest MedTech srl was created in 2019 and is actively working on a first project targeting mitral valve repair. Our objective is to bring our devices to first in human use and then to market. We work through active collaboration with scientific, industrial and financial partners.

Today, we are developing a new TMVr - transcatheter mitral repair solution. Mitral regurgitation is one of the most prevalent valvular heart disease in western markets. TMVr options are still limited. MithraX combines an annuloplasty and optimized leaflets coaptation, delivered via a catheter based intervention.

GABI SMARTCARE

HEARTKINETICS





B - 1435 MONT-SAINT-GUIBERT

E-mail: Isabelle.damman@gabismartcare.com

Website: www.gabismartcare.com

Linkedin: www.linkedin.com/company/gabismartcare

DELEGATE:

Jonathan BAUT, CEO

Mobile: +1 305 796 3050 - +32 49748 58 48 E-mail: Jonathan.baut@gabismartcare.com



Rue Auguste Piccard 48 B - 6041 GOSSELIES

E-mail: info@heartkinetics.com Website: heartkinetics.com

LinkedIn: https://www.linkedin.com/company/heartkine-

DELEGATES:

Pierre-François MIGEOTTE, CEO & Founder Email: pierre-francois@heartkinetics.com

David HAINE, CCO Mobile: +32474 98 90 28 Email: david@heartkinetics.com

Gabi SmartCare is a digital health company dedicated to revolutionizing pediatric care.

The early parenting journey meets constant change and new challenges, lacking support when it comes to their child's health. As a result, 38% of children visit emergency departments (30 million visits) each year and 40% of these are unnecessary. Pediatric care is ripe for innovation. While digital health innovations have successfully reduced healthcare costs and improved clinical outcomes for adults, pediatric care has been left behind (source).

PediarityTM from Gabi SmartCare is the first full stack solution that effectively helps parents provide the right care for their child at the right time at home. PediarityTM consists of a medical grade monitoring solution connected to a data-empowered medical team. Through the Gabi Analytics platform, millions of monitored data points are transformed into an interactive and actionable health report that allows the medical team to effectively assess the child's condition.

PediarityTM is deployed in clinical studies with leading institutions in Europe (Huderf, CHC Liege, UZA, Necker) and the United States (Columbia, Children's Mercy and Children's National in Washington DC). Commercial launch is expected for Q4 2023 following FDA clearance.

Gabi has secured multiple awards including Silicon Valley Bank and Blue Knight (Barda/Johnson & Johnson). The leadership team at Gabi is composed of passionate and experienced entrepreneurs, backed up with a clinical and strategic advisory board including KOLs from Columbia, Children's National and Necker amongst others.

Starting with a B2C approach to generate the right health economics, Pediarity brings peace of mind to parents while reducing unnecessary emergency visits and preventable hospital admissions. PediarityTM is deployed in clinical studies with leading institutions in Europe (Huderf, CHC Liege, UZA, Necker) and the United States (Columbia, Children's Mercy and Children's National in Washington DC). Commercial launch is expected for Q4 2023 following FDA clearance.

The company is raising its Series A funding aimed at financing the commercial launch.

HeartKinetics (HK), a MedTech dedicated to the remote screening and monitoring of patients with heart failure or patients with cancer at risk of developing heart failure. Created in 2019, HeartKinetics began in the space field thanks to technology for monitoring the heart function of astronauts during their stay in space. Building on the results obtained as part of this ESA-funded project, HeartKinetics now aims to revolutionize the management of heart failure, the leading cause of death worldwide with nearly 65 million cases recorded. HeartKinetics is revolutionizing cardiovascular diseases and patient management worldwide thanks to Al-based predictive technology able to intercept heart failure. KINO® is the first solution the company brings to the market (CE mark and FDA agreement are under approval). It combines (i) a mobile self-management app for heart failure patients, (ii) a web platform that supports healthcare professionals' decision-making, (iii) a cloud computing space where the Al-based technology turns data into predictive actionable insights for treatment efficacy. HeartKinetics KINO System is a complete innovative heart failure detection and monitoring solution using a smartphone and a novel cloud-based AI-driven algorithm for detecting early signs of HF. This system intends to record, store, and transfer cardiac and pulmonary vital signs obtained from the recording of cardiac-induced thoracic vibrations using a smartphone's internal motion sensors. KINO.cardio - the HCP version of the mobile app for the detection and monitoring of patients with HF. KINO.cardio can be used in combination with an ECG patch or stand-alone using only smartphone motion sensors. This solution is foreseen to be used at the emergency department to detect HF among dyspneic patients, and at the oncology department to detect the early signs of the cardiotoxic effect of cancer treatment (chemotherapy or targeted therapies) that has a negative impact on cardiac function; the application is expected to help triage patients that are sent to cardiology for diagnostic confirmation. KINO.pro - is a web application for HCP and a desktop extension of KINO.cardio, that provides access for HCP's to the patient's data analysis for better clinical management and care. KINO.home - the solution that allows patients to take measurements at home. The KINO.home is a device-less smartphone-based solution that is only using the patient's smartphone motion sensors to record cardiac activity for one minute every day to ensure easy follow-up or remote monitoring of HF progression. Data is securely stored in the KINO.core and accessible by the HCP from KINO.pro. HeartKinetics has recently entered Mayo Clinic Platform_Accelerate program.



LYS MEDICAL

NEUROPATH







Rue Auguste Piccard 48 B - 6041 GOSSELIES E-mail: info@lysmedical.com Website: www.lysmedical.com

DELEGATES:

Benjamin MERTENS, CEO Mobile: +32 478 34 61 99

E-mail: Benjamin.Mertens@lysmedical.com



Rue Jean Burger 2 B - 7850 ENGHIEN

E-mail: contact@neuropath.life Website: https://neuropath.life/

LinkedIn: www.linkedin.com/company/www-neuro-

path-life/

DELEGATES:

Benoît TAS, CEO

Mobile: +32 472 74 16 71

E-mail: benoit.tas@neuropath.life

Lys Medical develops innovative solutions in the field of lung cancer. We develop, manufacture, and certify endoscopic devices dedicated to provide the physicians a portfolio of solutions to improve the yield of biopsies during the lung cancer screening.

The lung cancer screening is a 7.7% growing market expected to reach \$2Bn by 2031. On a yearly basis, 3Mio lung cancer cases will be diagnosed and 11Mio bronchoscopic procedures will be performed by 2030.

Our strengths rely on our micro-design and manufacturing capabilities, with rapid prototyping and our regular presence in hospitals to collect feedbacks about our devices. With mastering of supply and sourcing from expert suppliers with cutting-edge technologies for manufacturing of components.

Lys Medical provides a unique reusable 1.85mm diameter miniaturized visualization probe and an associated disposable guiding sheath. They are dedicated to help in confirming the biopsy site. Our solution is CE-Marked and we are looking forward an FDA Clearance .In 2022, 100 patients were done and it was tested in 10 hospitals.

Over the past three years, we have developed a ready-to-use digital health platform for the follow-up of people with Parkinson's based on data reported by themselves and their caregivers on the one hand, and objective health parameters, movement and voice biomarkers on the other.

NeuroPath offers a disruptive solution to improve the care pathway of people with Parkinson for a better quality of life and lower costs. Throughout the patient journey, data are collected digitally through our active and passive CE Class I application NeuroPath Insights using a smartphone and Apple Watch. We let the patient and caregiver report symptoms, we analyse, categorize and alert the clinicians for risks and support clinical improvements. Our platform supports interdisciplinary clinical decisions, remote patient monitoring and remote therapeutics in-between consultations.

NeuroPath is part of a H2020 sponsored consortium led by HUS Helsinki which also involves Padova and the team of Angelo Antonini.

NeuroPath also has a legal entity in Chicago and is a member company of Matter Health and Polsky. We work closely with the Davis Phinney Foundation.

12 13

SYNERGIA MEDICAL





Rue Emile Francqui 6 B - 1435 MONT-SAINT-GUIBERT Website: www.synergia-medical.com LinkedIn: https://www.linkedin.com/company/synergia-medical/

DELEGATE:

Attila BORBATH, CEO Mobile: +32 497 40 47 67 E-mail: attila.borbath@synergiam.com MECATECH CLUSTER - Walloon Cluster in Mechanical Engineering



Business Village Ecolys
Avenue d'Ecolys 2 bte 33
B- 5020 NAMUR
E-mail: admin@polemecatech.be
Website: www.polemecatech.be
LinkedIn:
https://www.linkedin.com/company/p-le-mecatech

DELEGATE:

Engel CARSTEN, Head of MecaTech Mobile: +32 497 23 16 15

E-mail: Carsten.engel@polemecatech.be

Synergia Medical is a preclinical stage company who has the ambition to become a major player in the field of neural stimulation by bringing a disruptive new type of implantable neurostimulators to the market.

The company is led by a group of seasoned executives, supported by a strong team of KOL,including Prof. Dr. Levy (USA).

First device is an optoelectronic neurostimulator: by using optical fibers and quartz casing, the device will advance existing neural stimulation treatments, hence improving patients' quality of life and paving the way to new personalized therapies.

9 patent families already granted - out of a portfolio of 15. ISO 13485 since May 2015.

MecaTech is a competitiveness Cluster in Mechanical Engineering based in Wallonia (Belgium), gathering 300 members (180+ companies, Research Centers, University labs). Our mission is to create an industrial dynamic that generates jobs by setting up, carrying out and leading technological innovation projects in support of Walloon companies, research centres and universities. The priority is to develop collaborative industrial and commercial projects with an international dimension.

With our network, more than 151 projects have been engineered since 2006.

Our focus is on innovative products, equipment & processes with high added value in 4 technological fields:

- Advanced Materials ;
- Advanced Manufacturing;
- Mechatronics,
- Data Technologies (IoT, IA ...)

Many application domains are covered by our network and our projects, such as Energy, Medical Devices, Defence & security, Mobility, Construction or Industry.

MecaTech is involved in several European projects on the topic of Industry 4.0 such as the DREAM and GEMSTONE projects (EUROCLUSTER, Single Market Programme), or WALHUB, a European Digital Innovation Hub for Wallonia (EDIH, Digital Europe Programme). MecaTech is involved as associated partner in several projects on the topic of Materials such as ALLIHENTROP (INTERREG), FA-FIL (INTERREG).

MecaTech is responsible for the implementation of the regional circular economy plan Circular Wallonia on the fields of battery, metallurgy and mobility.

MecaTech is a network partner of EIT Manufacturing and EIT Raw Materials.

14 1!



WALLONIA EXPORT & INVESTMENT AGENCY

Place Sainctelette 2 B - 1080 BRUSSELS BELGIUM Phone:+32 2 421 82 11

info@awex.be www.awex-export.be Avenue des Dessus de Lives 6 B - 5101 NAMUR BELGIUM Phone: +32 81 33 28 50

welcome@investinwallonia.be www.investinwallonia.be









